How do you approach the subsequent management of a patient with appendiceal adenocarcinoma (T4bN2M1a) with completely resected single peritoneal and omental deposits?

This is a largely data-free zone when it comes to prospective trials but many excellent retrospective studies exist on the topic. There are data (NCDB, institutional and others) to suggest a benefit of adjuvant therapy (see Asare EA et al. Cancer 2016;122:213-21). I would look carefully at the grade...